AI in Healthcare October 2, 2024
Generative AI is fixing to transform the pharmaceutical industry. However, not all adopters will reap rewards in comparable degrees.
That’s because large companies will outspend smaller rivals by a lot. In the process, the dominant will gain an “enduring” competitive advantage over the rest of the field.
The prediction is in a new report from S&P Global.
Commenting on AI’s potential to speed development of new and improved drugs—one of the most hotly anticipated applications of the technology in the sector—the authors note the pace will be difficult to measure.
They point out the cycle from initial discovery to clinical trials to FDA approval to market presence currently takes an average 10 to 15 years. And they...
Today's Sponsors
Today's Sponsor